Erland Construction to Fit-out 28,900sf for Affini-T Therapeutics

Watertown, Mass. - Affini-T Therapeutics, a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has selected Erland, in collaboration with SmithGroup, to fit-out 28,900sf at 100 Forge (Arsenal Yards). Affini-T will occupy the entire top two floors of the 9-story building. The new space will include open office areas, conference and huddle rooms, specialty labs, tissue culture and analytical suites, wellness areas, dining areas, and a private wraparound balcony with views of the downtown Boston skyline, Charles River, and Western Hills of greater Boston.

Erland constructed 100 Forge, the 185,000sf base building that Affini-T is moving in to. The cutting-edge lab-ready building includes one level of below-grade parking as well as a 1-story enclosed mechanical penthouse above the highest occupiable level. The fit-out requires an extensive coordination effort to ensure that all the supply, exhaust and return ductwork, as well as process utilities and electrical, will fit above the ceiling. Material and equipment deliveries will be scheduled in advance and performed off hours when needed due to the concurrent construction activities taking place within 100 Forge.

“Having a modern and innovative workspace is crucial to the growth of Affini-T and we are impressed by the work at 100 Forge Arsenal Yards,” said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. “We look forward to establishing our presence within the Boston-area life science community. This space will enable our team to work collaboratively across the various functions of the organization to develop next-generation therapeutics for patients in need.”   

The project is slated to complete in January of 2023. This is Erland’s first time partnering with Affini-T.

“It is a privilege to be working with this dynamic group of industry leaders on what we believe will be an extremely successful suburban lab project given the state of the local life sciences market and the associated demand for high-quality working environments with access to luxury amenities,” said Jay Sturdivant, Advanced Technology/Life Sciences Group Manager, Erland. “We’re thrilled to be a part of it.”

About Affini-T Therapeutics
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Affini-T Contacts
Media Contacts
Danielle Cantey
Evoke Canale
Danielle.Cantey@evokegroup.com
619-826-4657

Ian Stone
Evoke Canale
Ian.stone@evokegroup.com
619-849-5388

Investor Contact
IR@affinittx.com

About Erland Construction
Over the past 45 years, Erland Construction has successfully grown into the Northeast’s leading open shop construction management firm. The Company is headquartered in Burlington, Massachusetts and has specialized expertise for new construction and renovations in major market sectors including advanced technology/life sciences, academic, corporate, commercial, residential, senior living, and hospitality. For more information, visit www.erland.com.